UNH vs VRTX
UNH: A diversified healthcare giant combining health insurance, pharmacy services, and healthcare data analytics to serve patients, providers, employers and governments across the value chain. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | UNH | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-08 close | $425.60 | $498.43 | |
| Market cap as of 2026-07-09 | $387.9B | $130.3B | |
| P/E as of 2026-07-09 | 32.20 | 30.05 | VRTX lower |
| PEG as of 2026-07-09 | 4.05 | 2.31 | VRTX lower |
| Net margin as of 2026-07-09 | +2.7% | +35.5% | VRTX higher |
| Gross margin as of 2026-07-09 | n/a | +86.2% | |
| Operating margin as of 2026-07-09 | +4.1% | +38.3% | VRTX higher |
| ROE as of 2026-07-09 | +12.4% | +23.9% | VRTX higher |
| ROA as of 2026-07-09 | +3.9% | +17.2% | VRTX higher |
| Debt / equity as of 2026-07-09 | 0.75 | 0.01 | VRTX lower |
| Revenue growth (YoY) as of 2026-07-09 | +9.7% | +10.1% | VRTX higher |
| Revenue CAGR (3y) SEC XBRL | +11.4% | +10.4% | UNH higher |
| Dividend yield as of 2026-07-09 | +2.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-09 | 0.63 | 0.29 | |
| 1-year return as of 2026-07-08 close | +38.3% | +6.9% | UNH higher |
Fundamentals: Finnhub, as of 2026-07-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.